Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

2.180 +0.050 (+2.35%)
Streaming Delayed Price Updated: 11:19 AM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 89,556
Open 2.130
Bid (Size) 2.180 (14,400)
Ask (Size) 2.200 (700)
Prev. Close 2.130
Today's Range 2.121 - 2.200
52wk Range 1.150 - 6.010
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
New to The Street Show #702 Airs Today on Bloomberg at 6:30 PM EST
Via ACCESS Newswire
News headline image
Three Revenue-Generating Facilities in Florida Plus Six More by Year-End in Expanding $750 Million Market Suicidal Depression Market: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News

Performance

YTD
-27.1%
-27.1%
1 Month
-30.8%
-30.8%
3 Month
-19.0%
-19.0%
6 Month
-15.5%
-15.5%
1 Year
+66.4%
+66.4%

More News

Read More
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs
Via Investor Brand Network
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 17, 2025 ↗
Via Benzinga
News headline image
Earnings Outlook For NRX Pharmaceuticals ↗
Via Benzinga
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
Via Investor Brand Network
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
$750 Million Market On Track to $3.35 Billion by 2034 Has High Return Opportunity with First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health: NRXP
Via Get News
MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida
Via Investor Brand Network
News headline image
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Via Benzinga
InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advancing Two-Pronged Approach to Bring Innovative Therapies to Market
Via Investor Brand Network
News headline image
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
MissionIRNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advances KETAFREE(TM), Expands Pipeline Targeting Urgent Needs
Via Investor Brand Network
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies
Via Investor Brand Network
News headline image
New to The Street Broadcasts Tonight on Bloomberg Featuring Roadzen, Metaterra, NRx Pharma, Blackbarn NYC, and Humanitarian Travel Group
Via ACCESS Newswire
BioMedNewsBreaks — NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Strengthens Pipeline with Dual Pathways for Ketamine-Based Therapies
Via Investor Brand Network
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition
Via Investor Brand Network
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Via Investor Brand Network
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
$750 Million Market Projected to Reach $3.35 Billion in 2034; Mega Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM)
Via Investor Brand Network
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is NRX Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, NRX Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does NRX Pharmaceuticals, Inc. - Common Stock trade on?
NRX Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock is NRXP on the Nasdaq Stock Market
What is the current price of NRX Pharmaceuticals, Inc. - Common Stock?
The current price of NRX Pharmaceuticals, Inc. - Common Stock is 2.180
When was NRX Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of NRX Pharmaceuticals, Inc. - Common Stock was at 11/24/25 11:19 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.